Details for Patent: 8,604,020
✉ Email this page to a colleague
Title: | Fluoroquinolone carboxylic acid molecular crystals |
Abstract: | Disclosed herein is a molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1-cyclopropyl-8-- chloro-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid. The molecular crystal is characterized by at least one of: (a) an X-ray powder diffraction ("XRPD") spectrum that comprises peaks at 2.theta. angles of 10.6, 15, 19.7, 21.1, and 22.degree..+-.0.2.degree.; (b) a DSC melting peak at 288.degree. C.; (c) a .sup.13C NMR spectrum having peaks at 23.3, 27.7, 41.1, 54.5, 116.6, and 153.5 ppm; and (d) pKa values of 5.65 and 9.91. The compound belongs to the class of fluoroquinolones and is useful as an antibacterial agent. |
Inventor(s): | King, Jr.; Harry M. (Webster, NY) |
Assignee: | Bausch & Lomb Incorporated (Rochester, NY) |
Filing Date: | Mar 14, 2013 |
Application Number: | 13/826,469 |
Claims: | 1. A pharmaceutical composition comprising a molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-1-azepin-1-yl)-1cyclopropyl-8- -chloro-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid characterized by an X-ray powder diffraction ("XRPD") spectrum that comprises peaks at 2.theta. angles of 10.6, 15, 19.7, 21.1, and 22.degree..+-.0.2.degree.; a DSC melting peak at 288.degree. C.; and a .sup.13C NMR spectrum having peaks at 23.3, 27.7, 41.1, 54.5, 116.6, and 153.5 ppm; wherein the pharmaceutical composition is a suspension comprising particles of said molecular crystal form. 2. A pharmaceutical composition comprising a molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1cyclopropyl-8-c- hloro-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid, wherein the molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1,4-dihydro-4-ox- oquinoline-3-carboxylic acid is characterized by an X-ray powder diffraction ("XRPD") spectrum that comprises peaks at 2.theta. angles of 10.6, 15, 19.7, 21.1, and 22.degree..+-.0.2.degree.; wherein the pharmaceutical composition is a suspension comprising particles of said molecular crystal form. 3. A pharmaceutical composition comprising a molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1cyclopropyl-8-c- hloro-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid, wherein the molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1,4-dihydro-4-ox- oquinoline-3-carboxylic acid is characterized by a differential scanning calorimetry ("DSC") melting peak at 288.degree. C.; wherein the pharmaceutical composition is a suspension comprising articles of said molecular crystal form. 4. A pharmaceutical composition comprising a molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1cyclopropyl-8-c- hloro-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid, wherein the molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1,4-dihydro-4-ox- oquinoline-3-carboxylic acid is characterized by an X-ray powder diffraction ("XRPD") spectrum that comprises peaks at 2.theta. angles of 10.6, 15, 19.7, 21.1, and 22.degree..+-.0.2.degree. and a .sup.13C NMR spectrum having peaks at 23.3, 27.7, 41.1, 54.5, 116.6, and 153.5 ppm; wherein the pharmaceutical composition is a suspension comprising particles of said molecular crystal form. |